Pilot Study Describing the Early Evolution of the Sexual Function of Patients Receiving Adjuvant Hormone Therapy for Breast Cancer
- Conditions
- Breast Cancer
- Registration Number
- NCT03395327
- Lead Sponsor
- Centre Hospitalier Departemental Vendee
- Brief Summary
The 2014-2019 cancer plan emphasizes the need to "reduce the impact of cancer on personal life".
The impact of cancer on sexuality is multifactorial: fatigue, anxiety, impaired body image, chemotherapy treatment.
None of these studies specifically assessed the early impact on the quality of sexual life of patients.
The purpose of this study is to describe to describe the early evolution of the quality of sexual life of patients receiving adjuvant hormone therapy for breast cancer.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- Female
- Target Recruitment
- 50
Inclusion Criteria
- Age greater than or equal to 18 years
- Female gender
- Histologically proven non-metastatic breast cancer
- Indication of adjuvant hormone therapy
- Patient able to understand a newsletter and to agree to participate
Exclusion Criteria
- Age under 18 years
- Pregnant woman
- Adjuvant chemotherapy
- Patient followed for heavy psychiatric pathology (requiring guardianship or trusteeship)
- Persons protected or deprived of their liberty
- Male
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method score FSFI (Female Sexual Function Index) 3 month after adjuvant hormone therapy
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
CHD Vendée
🇫🇷La Roche-sur-Yon, France